Table 2.

Outcomes in COVID-19 patients with and without pulmonary sarcoidosis before and after propensity score matching.

Outcome	Sarcoidosis group (n = 954)	Percentage	Non-Sarcoidosis group (n = 277317)	Percentage	Risk Ratio	95% CI Lower	95% CI Upper
Before propensity score matching
Mortality within 30 days	33	3.46	5004	1.80	1.92	1.37	2.68
Mortality within 60 days	41	4.30	5704	2.06	2.09	1.55	2.82
Inpatient services	185	19.40	24563	8.86	2.19	1.92	2.49
Critical Care	66	6.92	8455	3.05	2.27	1.80	2.87
Mechanical ventilation	42	4.40	5366	1.94	2.28	1.69	3.06
30-day composite outcome	58	6.08	8282	2.99	2.04	1.59	2.61
60-day composite outcome	62	6.50	8746	3.15	2.06	1.62	2.62
Acute Kidney Injury	97	10.17	10956	3.95	2.57	2.13	3.11
Renal replacement therapy	18	1.89	1192	0.43	4.39	2.77	6.96
Outcome	Sarcoidosis group (n = 954)	Percentage	Non-Sarcoidosis group (n = 954)	Percentage	Risk Ratio	95% CI Lower	95% CI Upper
After propensity score matching
Mortality within 30 days	33	3.46	42	4.40	0.79	0.50	1.23
Mortality within 60 days	41	4.30	45	4.72	0.91	0.60	1.38
Inpatient services	185	19.39	166	17.4	1.11	0.92	1.35
Critical Care	66	6.92	62	6.50	1.07	0.76	1.49
Mechanical ventilation	42	4.40	38	3.98	1.11	0.72	1.70
30-day composite outcome	58	6.08	62	6.50	0.94	0.66	1.32
60-day composite outcome	62	6.50	64	6.71	0.97	0.69	1.36
Acute Kidney Injury	97	10.17	88	9.22	1.10	0.84	1.45
Renal replacement therapy	18	1.89	13	1.36	1.39	0.68	2.81